Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial Belzutifan for advanced renal cell carcinoma was associated with improved disease-specific symptoms and QOL compared with everolimus. Taken together with the efficacy and safety data from LITESPARK-00...

Online first: Health-related quality of life with #belzutifan versus #everolimus for advanced #RenalCellCarcinoma #LITESPARK005: patient-reported outcomes from a randomised, open-label, phase 3 trial

www.thelancet.com/journals/lan...